These findings have important clinical implications, as they suggest that selective DAT inhibitors could be used in PD, perhaps early in the disease, as L-DOPA-sparing agents, a strategy that might be used to delay the onset of dyskinesia. This evidence concerns the gene SLC6A3 and Parkinson disease.